Pulmonary fibrosis
Conditions
Interventions
Observational group of ILAs, non-ILAs and ILD with lung nodule:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Part 1: Cross-Sectional Study 1. Participants with ILAs, non-ILAs, or ILD who underwent lung nodule resection surgery at West China Hospital, Sichuan University; 2. With chest HRCT (high-resolution computed tomography) at West China Hospital, Sichuan University within 1 month before hospitalization; 3. With appropriate lung tissue specimens corresponding to different ILAs abnormalities on HRCT (including normal region, ground-glass opacities, reticulations, traction bronchiectasis, non-emphysematous cysts, and honeycombing) based on the actual surgical approach; 4. Willing to participate and have signed the informed consent. Part 2: Cohort Study 1. Participants with ILAs who underwent lung nodule resection surgery at West China Hospital, Sichuan University; 2. With chest HRCT (high-resolution computed tomography) at West China Hospital, Sichuan University within 1 month before hospitalization; 3. With appropriate lung tissue specimens corresponding to different ILAs abnormalities on HRCT (including normal region, ground-glass opacities, reticulations, traction bronchiectasis, non-emphysematous cysts, and honeycombing) based on the actual surgical approach; 4. Willing to participate and have signed the informed consent.
Exclusion criteria
Exclusion criteria: Part 1: Cross-Sectional Study Exclusion Criteria: 1. Participants with a history or imaging findings of other pulmonary diseases, such as emphysema, bullae, bronchiectasis, pneumothorax, pleural effusion, COPD, or asthma; 2. Participants with acute or chronic pulmonary infections, including tuberculosis, bacterial/fungal/viral lung infections, etc.; 3. Participants who have undergone targeted therapy, immunosuppressive therapy, radiotherapy, or chemotherapy. Part 2: Cohort Study Exclusion Criteria: 1. Participants with a history or imaging findings of other pulmonary diseases, such as emphysema, bullae, bronchiectasis, pneumothorax, pleural effusion, COPD, or asthma; 2. Participants with acute or chronic pulmonary infections, including tuberculosis, bacterial/fungal/viral lung infections, etc.; 3. Participants who have undergone targeted therapy, immunosuppressive therapy, radiotherapy, or chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of ILAs progress to ILD;The proportion of ILAs with radiological progression;The proportion of ILAs showing significant decline in lung function (with an annual decline in FVC% predicted >=5% absolute value);The proportion of ILAs progress to other lung diseases;Proportion of ILAs (Incidental Lung Abnormalities) with concurrent pulmonary nodules, emphysema, and COPD;The mortality of ILAs during the follow-up period;Clinical Characteristics;Pulmonary Function Tests;Six Minute Walk Test;Blood Tests (routine, biochemistry, immuno-related, KL6);Chest CT;Pathological features;Multi-Omics Analysis; | — |
Countries
China
Contacts
Public ContactFengming Luo
West China Hospital, Sichuan University
Outcome results
None listed